Application of remdesivir in preparation of medicine for inhibiting cardiotoxicity of anti-tumor medicines

An anti-tumor drug and cardiotoxic technology, applied in the field of biomedicine, can solve problems such as heart damage and enhanced toxicity, and achieve the effect of improving application potential and market prospects

Active Publication Date: 2021-03-16
北京箭牧科技有限公司
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cardiotoxicity caused by anthracyclines is usually progressive and irreversible, and may cause cardiac damage on initial use
At the same time, the cardiotoxicity of anthracyclines is also closely related to the involved dose. For example, single high-dose medication, mediastinal radiotherapy, and combined use with cyclophosphamide, trastuzumab, and taxanes can all increase toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of remdesivir in preparation of medicine for inhibiting cardiotoxicity of anti-tumor medicines
  • Application of remdesivir in preparation of medicine for inhibiting cardiotoxicity of anti-tumor medicines
  • Application of remdesivir in preparation of medicine for inhibiting cardiotoxicity of anti-tumor medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Remdesivir effectively inhibits acute death caused by tumor drugs

[0032] 1. Experimental materials

[0033] 1. Experimental animals: C57BL / 6 mice, 8-week-old male, weighing 20-24 g, SPF grade, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.

[0034] 2. Remdesivir: Protect from light, seal, and dry at 4°C. Take an appropriate amount of medicine, dissolve it in 0.5% sodium carboxymethylcellulose, and make it 8mg / mL (relative to 80mg / kg). The 8mg / mL solution was diluted serially. Each animal was orally given 0.2mL / 20g by gavage according to body weight. Ready to use.

[0035] 3. Solvent: 0.5% sodium carboxymethylcellulose (CMC).

[0036] 2. Experimental group

[0037] a) Control group (negative control): C57BL / 6 mice

[0038] b) ADM group + solvent

[0039] c) ADM group + remdesivir (10mg / kg, po, QD)

[0040] d) ADM group + remdesivir (20mg / kg, po, QD)

[0041] 3. Experimental steps

[0042] 1. Select mice with equal wei...

Embodiment 2

[0069] Example 2 Remdesivir has cardioprotective effect against the cardiotoxicity of anti-tumor drugs

[0070] 1. Experimental materials

[0071] With embodiment 1.

[0072] 2. Experimental group

[0073] With embodiment 1.

[0074] 3. Experimental steps

[0075] 1. Construct the ADM-induced mouse model and start to treat with different concentrations of remdesivir on the same day, and administer it continuously orally.

[0076] 2. Mice with a cumulative toxicity of 20 mg / kg underwent echocardiography after the 10th day of treatment with Remdesivir, and mice with a cumulative toxicity of 18 mg / kg underwent echocardiography after the 24th day of treatment with Remdesivir to detect changes in cardiac function in the mice , and perform data analysis.

[0077] 4. Experimental method

[0078] 1. Echocardiographic detection: put the mice in the pre-sedation chamber, use 3% isoflurane, 1000mL / min to induce anesthesia, take the mouse out of the pre-session chamber after the rig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of remdesivir in preparation of a medicine for inhibiting cardiotoxicity of anti-tumor medicines. The invention confirms significant potential of the retegravir asa medicine for inhibiting the cardiotoxicity of anti-tumor medicines, discloses good curative effects of the retegravir on the cardiotoxicity caused by the anti-tumor medicines for the first time, provides an effective novel potential alternative medicine for treating the cardiotoxicity of the anti-tumor medicines, expands indications of the retegravir, and greatly improves application potential and market prospect of the retegravir.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to the application of remdesivir in the treatment of antitumor drug cardiotoxicity and myocardial protection. Background technique [0002] Remdesivir (RDV, GS-5734) is a nucleoside analog antiviral drug developed by Gilead Sciences (GILD) that works by inhibiting viral nucleic acid synthesis. [0003] In the patent WO2009132123A1, the general formula of the compound structure of Remdesivir was proposed for the first time, which is used for the treatment of hepatitis C virus infection, dengue fever and other flaviviridae virus infection diseases. Patent WO2012012776A1 proposes the effect of Remdesivir in treating diseases infected by Paramyxoviridae viruses. In subsequent patents, it is also proposed that RDV can be used as an anti-filovirus, anti-arenavirus and anti-coronavirus drug. According to the literature information, the anti-tumor drug cardiotoxicity inhibitory effect o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/685A61K45/06A61P9/00A61P9/10A61P9/06A61P9/12A61P9/02A61P9/04
CPCA61K31/685A61K45/06A61P9/00A61P9/10A61P9/06A61P9/12A61P9/02A61P9/04
Inventor 崔庆华周宛露
Owner 北京箭牧科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap